Cargando…
ACT001 Inhibits TLR4 Signaling by Targeting Co-Receptor MD2 and Attenuates Neuropathic Pain
Neuropathic pain is a common and challenging neurological disease, which renders an unmet need for safe and effective new therapies. Toll-like receptor 4 (TLR4) expressed on immune cells in the central nervous system arises as a novel target for treating neuropathic pain. In this study, ACT001, an o...
Autores principales: | Zhang, Tianshu, Lin, Cong, Wu, Siru, Jin, Sha, Li, Xiaodong, Peng, Yinghua, Wang, Xiaohui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218074/ https://www.ncbi.nlm.nih.gov/pubmed/35757727 http://dx.doi.org/10.3389/fimmu.2022.873054 |
Ejemplares similares
-
Cannabidivarin alleviates neuroinflammation by targeting TLR4 co-receptor MD2 and improves morphine-mediated analgesia
por: Wang, Xue, et al.
Publicado: (2022) -
Nicotine and its metabolite cotinine target MD2 and inhibit TLR4 signaling
por: Li, Hongyuan, et al.
Publicado: (2021) -
Pentamidine Alleviates Inflammation and Lipopolysaccharide-Induced Sepsis by Inhibiting TLR4 Activation via Targeting MD2
por: Wu, Siru, et al.
Publicado: (2022) -
Demethyleneberberine alleviated the inflammatory response by targeting MD-2 to inhibit the TLR4 signaling
por: Zhao, Yaxing, et al.
Publicado: (2023) -
Selective targeting of MD2 attenuates intestinal inflammation and prevents neonatal necrotizing enterocolitis by suppressing TLR4 signaling
por: Huang, Dabin, et al.
Publicado: (2022)